Franklin Stuart Friedman is Director at Deciphera Pharmaceuticals, Inc. (DCPH). They have made 1 open-market trade across 1 company since 2023, most recently 2024-06-11.
CIK 0001794351
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $139K since 2023, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| DCPH | 10,000 | $256K |
Shares reported on the most recent Form 4, priced at the 2023-06-12 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| DCPH | BUY | 2023-06-08 | 2023-06-12 | $13.88 | $139K | +2.7% | -3.1% | -4.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.